drugset / Trial / NCT02482272
Compare Continuing Lamivudine Plus Adefovir or Adefovir Versus Switching to Entecavir Plus Adefovir in Patients With LAM-resistant Chronic Hepatitis B
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to compare efficacy and safety of continuing Lamivudine plus Adefovir or Adefovir versus switching to Entecavir plus Adefovir in patients with LAM-resistant chronic hepatitis B who have suboptimal response to Lamivudine plus Adefovir or Adefovir
Timeline
- Start
- 2015-05
- Primary completion
- 2017-01
- Completion
- 2017-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Entecavir | Small molecule | 1 mg | Oral |
| Comparator | Lamivudine | Other / unclassified | 100 mg | Oral |
| Background | Adefovir | Unknown | 10 mg | Oral |